Phase 2 study

Not yet recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Not yet recruiting
Phase Phase 2
Sponsor LaNova Medicines Limited
Registry number NCT07694765
Started 15 July 2026 Today 16 October 2026 Estimated completion 31 December 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Macquarie University North Ryde NSW Status not stated
Cancer Care Wollongong Hospital Wollongong NSW Status not stated
Icon Cancer Centre South Brisbane Brisbane QLD Status not stated

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 90

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

1. Participants who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.

2. Participants must be ≥18 years or the legal age of consent at the time of signing the ICF.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

4. Life expectancy ≥ 3 months.

5. Adequate organ and bone marrow function as defined by protocol.

6. Participants who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion Criteria:

1. Participant in any other clinical trial within 28 days prior to 1st dosing of LM-364.

2. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of CTCAE v6.0.

3. Participants with uncontrolled tumour-related pain.

4. Use of any live attenuated vaccines within 28 days prior to 1st dosing of LM-364.

5. Participants who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-364.

6. Participants who have severe cardiovascular disease.

7. Participants who have uncontrolled or severe illness.

8. Participants who have a history of immunodeficiency disease.

9. Participants with a known history of autoimmune disease.

10. Participants who have other active malignancies which are likely to require the treatment.

11. Child-bearing potential female who have positive results in pregnancy test or are lactating.

12. Participants who have psychiatric illness or disorders that may preclude study compliance.

13. Participants who is judged as not eligible to participate in this study by the investigator.

Dates on the record

Started 15 July 2026
Estimated completion 31 December 2028
Registry last updated 10 July 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 10 July 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.